The Food and Drug Administration is scheduled to decide by June 20 whether to approve cytisinicline as a smoking cessation aid — an outcome that, if positive, would introduce the first new pharmacological treatment for nicotine dependence since varenicline (Chantix) gained approval in 2006.
Cytisinicline is a plant-derived partial agonist of the α4β2 nicotinic acetylcholine receptor subtype, the same molecular target as varenicline. It is extracted from the common laburnum tree (Cytisus laburnum) and has been used as a smoking cessation treatment in Eastern Europe since the 1960s under the brand name Tabex — an unusually long real-world record for a drug now seeking Western regulatory approval — but without the double-blind, placebo-controlled evidence package the FDA requires.
Achieve Life Sciences conducted two U.S. Phase 3 trials, ORCA-2 and ORCA-3, both of which met their primary endpoint. In ORCA-3, the continuous abstinence rate at weeks 9–12 was 30.3% for cytisinicline versus 9.4% for placebo — a statistically significant difference consistent in magnitude with the benefit seen with varenicline in that endpoint. The NDA is based on the ORCA programme.
Achieve holds Breakthrough Therapy Designation for cytisinicline in electronic cigarette and vaping cessation — a separate indication from the smoking cessation NDA under review. A Commissioner’s National Priority Voucher attached to the programme similarly references the vaping indication. The June 20 PDUFA concerns the smoking NDA and rests on the ORCA data alone.
Varenicline was withdrawn from the U.S. market in 2021 due to nitrosamine impurity concerns and returned as a reformulated generic in 2022. Cytisinicline has a distinct chemical structure and independent manufacturing profile; the sponsor has provided a nitrosamine impurity assessment as part of its NDA submission.
If approved, cytisinicline would enter a market currently served by nicotine replacement therapy, varenicline, and bupropion. Pricing and reimbursement terms have not been disclosed. The drug is currently available in some European countries without prescription; a U.S. launch would require domestic manufacturing capacity.